drugset / Trial / NCT02160262

Open-label Safety Study in Adults With ADHD

NCT02160262

Phase 3 Completed 724 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)

Timeline

Start
2014-06
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasotraline Small molecule 4 mg
Subject Dasotraline Small molecule 6 mg
Subject Dasotraline Small molecule 8 mg